Recent advances and future perspectives in non-small cell lung cancer immunotherapy
Journal of Human Biology and Clinical Medicine · 2026
DOI: 10.63621/jhbcm/3.2026.46 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Human Biology and Clinical Medicine, 2026. Verfasst von Nurgul Sadyrova und 4 weiteren Autor:innen.
Abstract (Originalsprache)
The introduction of immune checkpoint inhibitors has transformed therapeutic strategies for non-small cell lung cancer; however, the generalisation of data regarding their molecular mechanisms of action and predictors of therapeutic efficacy remains an important challenge. The aim of this study was to conduct a comprehensive analysis of the molecular and biological principles underlying immune checkpoint inhibitors, to identify prognostic biomarkers of treatment response, and to synthesise current combination immunotherapeutic strategies for non-small cell lung cancer. This work was performed as a systematic review of scientific publications in the PubMed, Web of Science, and Scopus databases for the period 2016-2025, using comparative analysis, systematic synthesis, and critical appraisal of randomised phase III trials, prospective multicentre cohort studies, and meta-analyses. In patients with PD-L1 expression ≥50%, pembrolizumab monotherapy was associated with a median overall survival of 26.3 months compared with 13.4 months for chemotherapy, with five-year survival rates of 31.9% and 16.3%, respectively. In contrast, the combination of immunotherapy and chemotherapy achieved approximately 20% five-year survival irrespective of PD-L1 expression. A high tumour mutational burden correlated with an objective response rate of 47.6%, compared with 27.3% in patients with low mutational burden, while high-grade microsatellite instability was associated with a 65% reduction in mortality risk (hazard ratio 0.35). It was established that KRAS/STK11 and KRAS/KEAP1 alterations are associated with an immunosuppressive phenotype and reduced efficacy of monotherapy, whereas the combination of anti-angiogenic agents with immune checkpoint inhibitors and chemotherapy achieved the longest median overall survival of 28.88 months. The findings provide a basis for the individualisation of therapeutic approaches using comprehensive biomarker panels and support the feasibility of multi-level patient stratification based on molecular genetic profiling, characterisation of the tumour microenvironment, and microbiome analysis to improve outcomes of immunotherapy in non-small cell lung cancer
Zitieren
APA
Sadyrova, N., Muratov, Z., Tashpolotova, A., Izabekov, B., & Abdykaiymova, G. (2026). Recent advances and future perspectives in non-small cell lung cancer immunotherapy. Journal of Human Biology and Clinical Medicine. https://doi.org/10.63621/jhbcm/3.2026.46
Vancouver
Sadyrova N, Muratov Z, Tashpolotova A, Izabekov B, Abdykaiymova G. Recent advances and future perspectives in non-small cell lung cancer immunotherapy. Journal of Human Biology and Clinical Medicine. 2026. doi:10.63621/jhbcm/3.2026.46
BibTeX
@article{Sadyrova2026,
author = {Sadyrova, Nurgul and Muratov, Zhanibek and Tashpolotova, Anarkan and Izabekov, Bekzat and Abdykaiymova, Gulum},
title = {Recent advances and future perspectives in non-small cell lung cancer immunotherapy},
journal = {Journal of Human Biology and Clinical Medicine},
year = {2026},
doi = {10.63621/jhbcm/3.2026.46}
}
EUVIMED